Insmed reported $216.52M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Cytokinetics USD 124.43M 2.17M Mar/2026
DBV Technologies USD 235.6M 98.78M Dec/2025
Gilead Sciences USD 1.24B 1000K Mar/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Insmed USD 216.52M 2.27M Mar/2026
Novartis USD 1.91B 60K Mar/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Sarepta Therapeutics USD 105.57M 607K Mar/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vertex Pharmaceuticals USD 254.2M 200K Mar/2026